EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, John J P Kastelein, Christie M Ballantyne, Kausik K Ray, Ann Marie Navar, Steven E Nissen iD, Mariko Harada-Shiba, Danielle L Curcio, Annie Neild, Douglas Kling und 12 weitere

New England Journal of Medicine · 03.07.2025 · 393 (1) · 51-61

DOI: 10.1056/nejmoa2415820 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 03.07.2025. Verfasst von Stephen J Nicholls und 23 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Heart Institute, Monash University, Clayton, VIC, Australia. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Cardiovascular Diseases, Cholesterol Ester Transfer Proteins, Cholesterol, LDL. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NewAmsterdam Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, LDLHyperlipoproteinemia Type IIAdultAgedFemaleHumansMaleMiddle AgedAtherosclerosisCholesterol, HDLDouble-Blind MethodHeart Disease Risk Factors

Substanzen

Anticholesteremic AgentsCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDL

Autor:innen und Institutionen

  • Victorian Heart Institute, Monash University, Clayton, VIC, Australia.
  • NewAmsterdam Pharma, Amsterdam.
  • Department of Vascular Medicine, University of Amsterdam, Amsterdam.
  • Baylor College of Medicine, Houston.
  • Texas Heart Institute, Houston.
  • Imperial College London, London.

ORCID-Profile: Steven E Nissen

Förderung

  • NewAmsterdam Pharma

Zitieren

APA

Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Navar, A. M., Nissen, S. E., Harada-Shiba, M., Curcio, D. L., Neild, A., Kling, D., Hsieh, A., Butters, J., Ference, B. A., Laufs, U., Banach, M., Mehran, R., Catapano, A. L., …, & BROADWAY Investigators (2025). Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. New England Journal of Medicine, 393(1), 51-61. https://doi.org/10.1056/nejmoa2415820

Vancouver

Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. New England Journal of Medicine. 2025;393(1):51-61. doi:10.1056/nejmoa2415820

BibTeX
@article{Nicholls2025,
  author = {Nicholls, Stephen J and Nelson, Adam J and Ditmarsch, Marc and Kastelein, John J P and Ballantyne, Christie M and Ray, Kausik K and Navar, Ann Marie and Nissen, Steven E and Harada-Shiba, Mariko and Curcio, Danielle L and Neild, Annie and Kling, Douglas and Hsieh, Andrew and Butters, Julie and Ference, Brian A and Laufs, Ulrich and Banach, Maciej and Mehran, Roxana and Catapano, Alberico L and Huo, Yong and Szarek, Michael and Balinskaite, Violeta and Davidson, Michael H and BROADWAY Investigators, BROADWAY Investigators},
  title = {Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {1},
  pages = {51--61},
  doi = {10.1056/nejmoa2415820}
}
Kostenlos starten →